Navigation Links
Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
Date:6/3/2011

SAN DIEGO, June 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.  Orexigen sought the meeting to gain clarity on the approval deficiency stated in the Complete Response letter the Company received on January 31, 2011.  The Complete Response letter requested that the Company conduct a randomized, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the drug's benefit-risk profile.  

Orexigen submitted a specific proposal to address the theoretical cardiovascular risk cited in the approval deficiency and also explored approval for a narrowed indication in patients with lower cardiovascular risk until data from the proposed outcomes trial could be reviewed for label expansion.  The Division of Metabolic and Endocrinologic Products (DMEP) advised Orexigen that the proposed cardiovascular outcomes trial would not adequately address the approval deficiency and instead, requested a pre-approval cardiovascular outcomes trial that Orexigen believes is unprecedented and would generate significantly more information than is necessary or feasible.  Additionally, DMEP stated that it would not consider approving Contrave for a narrowed population without first reviewing data from a cardiovascular outcomes trial.  Finally, DMEP said that it intends to hold a general advisory committee early next year to discuss cardiovascular assessment for obesity therapeutics, and that any agreement reached on the desi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)...  Bayer HealthCare and Orion Corporation, a pharmaceutical ... , have begun to enroll patients in a ... androgen receptor inhibitor in clinical development. The study, ... prostate cancer who have rising Prostate Specific Antigen ... is designed to determine the effects of the ...
(Date:9/15/2014)...  Patients in today,s changing health care landscape are ... outpatient setting versus a hospital. In an effort to ... patients continue to receive high quality medical care; Kaiser ... internal medicine residency program. The program,s progressive curriculum will ... and even virtual settings. "We are ...
(Date:9/15/2014)... and BRUSSELS , Sept. 15, 2014 ... UCB (Euronext Brussels:UCB) today announced results from several exploratory ... postmenopausal women with low bone mineral density (BMD). Romosozumab ... work by inhibiting the protein sclerostin, thereby increasing bone ... at the American Society for Bone and Mineral Research ...
Breaking Medicine Technology:Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15
... Publicis Groupe announced today that ... Healthcare Communications Group (PHCG), powerfully redefining Publicis Groupe,s ... healthcare sector. PHCG is the world,s ... Digitas Health and Razorfish Health -- Publicis Groupe,s ...
... 27, 2011 Halozyme Therapeutics, Inc. (NASDAQ: ... targeting the extracellular matrix for the diabetes, ... results from a study in patients with type 1 ... Phase 1b study was conducted as a randomized, double-blind, ...
Cached Medicine Technology:Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 2Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 3Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 4Publicis Healthcare Communications Group Redefines Publicis Groupe's Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health 5Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial 2Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial 3Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial 4
(Date:9/16/2014)... 16, 2014 Non-small cell lung cancer (NSCLC) survivors ... at the time of diagnosis have a lower ... compared to those who are current smokers, suggesting ... higher risk of SPLC, according to research presented ... (ASTRO,s) 56th Annual Meeting. , The analysis studied ...
(Date:9/16/2014)... 16, 2014 An experimental positron emission ... disease while a person is still alive, according to ... Medicine at Mount Sinai, and at Molecular Neuroimaging (MNI) ... the journal Translational Psychiatry. , Specifically, the study results ... which is designed to latch onto a protein called ...
(Date:9/16/2014)... VA (PRWEB) September 16, 2014 Gary ... Republic of China, has selected Worldwide Speakers Group for ... former U.S. Secretary of Commerce and Governor of Washington, ... foremost authorities on U.S.-China relations, global expansion, and business ... on global competitiveness and how to grow an organization’s ...
(Date:9/16/2014)... September 16, 2014 The Muscular ... of flu vaccines for individuals affected by muscle ... and other neuromuscular diseases. , MDA offers this ... muscle disease who, because of compromised respiratory function ... the lungs — are at increased risk of ...
(Date:9/16/2014)... Insuranceservicecompany.com has released a new blog post explaining ... , Whole life insurance can provide financial security for ... an investment tool. Clients can save money for retirement using ... A whole life insurance plan features a savings account which ... this policy to be profitable, clients should purchase it as ...
Breaking Medicine News(10 mins):Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 2Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2Health News:MDA Offers Flu Shots to Those Affected by Muscle Disease 2Health News:Whole Life Insurance Can Be A Good Investment Tool for Retirement! 2
... The Midwest Center for Stress and Anxiety announced ... the premier online destination for news, information and solutions ... new site features an enhanced user interface with access ... most pressing and relevant stress-related issues, and the newest ...
... Arizona Technology Enterprises (AzTE), the technology venturing arm ... technology forum for investors on Feb. 12 and 13, ... in Scottsdale, AzTE collaborated with its tech transfer partner, ... The forum was sponsored and supported by Silicon ...
... FRANCISCO, Feb. 18 DIAKADI Body, Personal ... its outdoor boot camps, the hottest and most economical workout ... a.m., individuals of all fitness levels will gather in Mission ... Stairs) to take their workout to the next level. ...
... Verathon(R) is pleased to announce,the GlideScope(R) Ranger Video ... States Army.(1) This certificate allows the,device to be ... of the most,demanding military settings. , ... The U.S. Army Airworthiness ...
... Achieves 20% Sales Growth over Q3 FY 08 and Record Quarterly ... ) today announced results for the quarter ended January 23, 2009. ... of fiscal 2009 compared to the third quarter of fiscal 2008 ... Net sales of $35.3 million, a 20% increase ...
... proves faster, more accurate in early tests , , WEDNESDAY, ... make prescribing the widely used anticoagulant warfarin safer by ... , The U.S. Food and Drug Administration estimates that ... blood clots that can cause strokes. Reasons range from ...
Cached Medicine News:Health News:The Midwest Center for Stress and Anxiety Re-launches Website for Stress, Anxiety, and Depression 2Health News:Arizona Technology Enterprises (AzTE) Hosts the ASU Tech Forum for the Investment Community 2Health News:Arizona Technology Enterprises (AzTE) Hosts the ASU Tech Forum for the Investment Community 3Health News:Arizona Technology Enterprises (AzTE) Hosts the ASU Tech Forum for the Investment Community 4Health News:Back by Popular Demand! DIAKADI Body Announces Its Spring Edition of Outdoor Boot Camps 2Health News:Back by Popular Demand! DIAKADI Body Announces Its Spring Edition of Outdoor Boot Camps 3Health News:GlideScope(R) Ranger Video Laryngoscope by Verathon(R) Awarded Airworthiness Certification by U.S. Army 2Health News:GlideScope(R) Ranger Video Laryngoscope by Verathon(R) Awarded Airworthiness Certification by U.S. Army 3Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 2Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 3Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 4Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 5Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 6Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 7Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 8Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 9Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 10Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 11Health News:Genetics May Help Fine-Tune Warfarin Dosage 2Health News:Genetics May Help Fine-Tune Warfarin Dosage 3Health News:Genetics May Help Fine-Tune Warfarin Dosage 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: